# Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen

> **NCT01457885** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 75 (actual)

## Conditions studied

- Acute Myeloblastic Leukemia

## Interventions

- **DRUG:** Clofarabine/Busulfan x 4
- **PROCEDURE:** Peripheral blood stem cell transplant

## Key facts

- **NCT ID:** NCT01457885
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-11
- **Final completion:** 2016-06-14
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2017-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457885, "Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01457885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*